Androclus' AT-001 fails RA Phase II

Androclus (San Diego, Calif.) said oral AT-001 missed the primary endpoint of under the curve of ACR20 response rates at days 112, 140 and 168 in a double-blind, placebo-controlled, U.S. Phase II tria...